This is not just another tool to image cancer. The probe is a two-for-one: detect cancer and distinguish one type from another. Together, they develop a cancer fingerprint.
Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers at Michigan Technological University hope to reduce that timeframe down to minutes.
A collaborative team of chemists and engineers from Michigan Tech lays the groundwork for this vision in two new papers. In the Royal Society of Chemistry’s journal Chemical Communication (DOI: 10.1039/c7cc09809j), the team explains the basic science behind multicolor probes that enable targeting of a cancer-relevant fructose transporter, delving into the image-based detection of cancer cells. In the journal Biosensors (DOI: 10.3390/bios8020039), the team addresses applications for breast cancer detection and differentiating nonmalignant, pre-malignant and malignant cancer cells.
GLUT5 transports fructose and cancer loves sugar
Two Michigan Tech researchers collaborated on the studies. Marina Tanasova, assistant professor of chemistry, and Smitha Rao, assistant professor of biomedical engineering, turned a 10-minute office meeting into a two-year collaboration built on a tiny fluorescent probe that seeks out the fructose transporter named GLUT5.
Cells need carbohydrates; facilitative glucose transporters (GLUTs) bring nutrients in and out of cells. When metabolic swings kick in—say, from cancer development—the overall make-up of GLUTs change so that more or less GLUTs are active. Fructose transporters like GLUT5 are of particular interest because of the direct connection between fructose uptake and cancer development, which also changes as cancer progresses and becomes malignant.
In their Chemical Communications paper, Tanasova and Rao’s team report on the design and validation of the fluorescent probes, called ManCous, to observe GLUT5 activity in a cell. They document the multicolored fluorescence that distinguishes GLUT5-rich cells from those deficient in GLUT5. The follow up Biosensors paper provides a proof-of-principle use of these probes as tools to assess and compare GLUT5 and metabolic activity of different cell types, including normal cells and different cancer subtypes.
“We came closer to a basic screening of cells’ GLUT composition—one that both detects cancer and distinguishes type,” Tanasova says, adding that while the concept is elegant, developing the technology is not easy. “From basic science to application, there is a lot of transformation that has to happen.”
Engineering better cancer detection takes collaboration
By better understanding the science behind sugar transporters, the team is more equipped to build technology that captures an accurate and precise GLUT fingerprint of cancerous cells.
“This probe is like a Swiss army knife,” Rao says, explaining that cancer detection is not the only use for the probe. “The more we learn about cancer through these probes, the more opportunities we have to apply them—which means more chances to treat different cancers, hopefully cure them, and at least prevent their spread and maximize drug delivery.”
What makes the probe so versatile is its ability to not only seek out and highlight cancer cells, but also to reveal the metabolic nuances of different stages of cancer development. While cancer generally gobbles up fructose, the GLUT5 and metabolic activity of nonmalignant, pre-malignant and malignant breast cancer cells do vary, which is what Rao, Tanasova and their team explored in the Biosensors paper. They found that ManCou probes allow for parallel analysis and quantification of GLUT5 and metabolic activity of cells just after a 10-minute incubation period. The notable differences in fluorescence intensity observed between normal cells and cancer cells, as well as different cancer types, provide important points of differentiation between different cell types and make these probes promising tools for cancer detection and diagnostics.
The Latest on: Cancer fingerprint
via Google News
The Latest on: Cancer fingerprint
- Multipass spectroscopy promises improved detection of cancer markers in breathon November 25, 2020 at 9:14 am
Detecting common diseases and illnesses by identifying telltale chemical compounds in exhaled breath has been a goal of biophotonics developers for several years. In the case of cancer, specific ...
- Alabama man who confessed to 1995 cold case murder said he was ready to 'meet his maker'on November 24, 2020 at 6:13 am
Johnny Dwight Whited (right), 53, called Decatur, Alabama, police on Wednesday saying he wanted to confess to the murder of Christopher Alvin Dailey (left) so as to 'lift a weight from his chest.
- Court: Texas, Louisiana can end Planned Parenthood fundingon November 23, 2020 at 12:54 pm
A federal appeals court ruled Monday that Texas and Louisiana can cut off Medicaid funding to Planned Parenthood clinics — a move supported by opponents of legal abortion, but ...
- FDA Grants Breakthrough Designation to 4D Path for Novel Cancer Diagnostic Solutionon November 19, 2020 at 12:05 pm
D Path, creator of a patented computer-aided cancer diagnostic and precision oncology platform, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough ...
- Steve Hewlett's reputation could be the latest casualty of the Martin Bashir Diana scandalon November 19, 2020 at 7:50 am
His journalistic credentials were impeccable, and his battle with cancer made him a national treasure. But did Steve Hewlett go too far?
- One Man’s Search for the DNA Data That Could Save His Lifeon November 19, 2020 at 4:05 am
The genetic correlations that could help Bryce Olson find a drug that works against his cancer are a scattered mess. Why don’t we have a better system for analyzing this kind of information?
- Europe ‘missing out’ on major cancer advances, says health experton November 18, 2020 at 5:44 am
Biomarker testing holds the potential to revolutionise early diagnosis and prevention of cancer. But the EU has not yet managed to fully capitalise on these advances, according to health experts.
- VolitionRx Ltd. (VNRX) CEO Cameron Reynolds on Q3 2020 Results - Earnings Call Transcripton November 16, 2020 at 2:45 pm
Q3 2020 Earnings Conference Call November 13, 2020 8:30 AM ET. Company Participants. Scott Powell - EVP, IR. Cameron Reynolds - President and CEO. D ...
- Dietary 1H-NMR “Fingerprints” Could Help Fight Against Chronic Diseaseon November 13, 2020 at 7:22 am
What we are doing is taking the whole pattern, the metabolic fingerprint of the urine ... Chemical Biology in the Department of Surgery and Cancer at Imperial College, in London, UK.
via Bing News